-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Niagen Bioscience, Lowers Price Target to $11

Benzinga·05/11/2026 11:06:06
Listen to the news
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Niagen Bioscience (NASDAQ:NAGE) with a Buy and lowers the price target from $12 to $11.